durvalumab (Imfinzi)
durvalumab is an FDA-licensed reference biologic from AstraZeneca UK Ltd. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2017
Reference approved
Reference product
Imfinzi durvalumab
AstraZeneca UK Ltd
- Approved
- May 01, 2017
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Molecular structure
Experimental 3D structure for durvalumab from the RCSB Protein Data Bank (PDB 5XJ4).
Interactive biological assembly from PDB entry 5XJ4. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here — no need to leave the page.
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for durvalumab, in chronological order.
Reference approval
Approval date of the reference durvalumab product.
9 yr 4 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
in 5 yr 6 mo
Frequently asked questions
Are there biosimilars approved for durvalumab (Imfinzi)?
No 351(k) biosimilars or interchangeable biosimilars referencing durvalumab are listed in the FDA Purple Book yet.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.